This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ABT-639
Description: ABT-639 is a selective voltage-dependent T-type calcium channel blocker that has little or no activity at other calcium channels, including N-, L-, or P/Q types. Following oral administration, ABT-639 dose dependently reduced nociception in animal models of chronic joint and neuropathic pain.
Additional information available to subscribers only: